Alys Pharmaceuticals
Signal active
Organization
Contact Information
Overview
Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.
About
Industries
Biotechnology, Health Care, Pharmaceutical
Founded
2024
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Alys Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $1.2B in funding across 12 round(s). With a team of 11-50 employees, Alys Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Alys Pharmaceuticals, raised $100.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
1
Lead Investors
0
Total Funding Amount
$100.0M
Details
1
Alys Pharmaceuticals has raised a total of $100.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2024 | Seed | 100.0M |
Investors
Alys Pharmaceuticals is funded by 3 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Francesco Rubertis | - | FUNDING ROUND - Francesco Rubertis | 100.0M |
| Alys Pharmaceuticals | - | FUNDING ROUND - Alys Pharmaceuticals | 100.0M |
| Medicxi | - | FUNDING ROUND - Medicxi | 100.0M |
Recent Activity
There is no recent news or activity for this profile.